Long Shortz with Neurizon Therapeutics: Strong confidence remains as FDA review delayed

Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn after the FDA has delayed its review of the company’s response to the NUZ-001 clinical hold until October 3rd.

Thurn assures investors the delay is not due to the submission or drug candidate, but rather capacity constraints of the FDA.

While disappointed, the company remains confident in NUZ-001’s potential and is working with US neurologists, key opinion leaders, and patient groups to advocate for a faster review.

In the meantime, Neurizon expects to release top-line results from its open-label extension study as soon as next week.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.